Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) does not directly speed up your resting metabolic rate, but it does change the body's relationship with hunger and energy intake in ways that lead to meaningful weight loss. Clinical trials reported an average reduction of around 15% of body weight over 68 weeks at the 2.4mg maintenance dose. The mechanism is more nuanced than a simple metabolic boost — and understanding it matters if you're weighing up whether this treatment is right for you. Wegovy is a prescription-only medicine; a prescriber decides clinical suitability after a full assessment, not a checklist.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Imagine you're two months into Wegovy. The nausea from the early weeks has largely settled, your portions are smaller without any conscious effort, and the between-meal snacking has almost stopped. It can feel like your metabolism has been switched into a different gear. In a sense, something has changed, but it is not your resting metabolic rate that has been turned up.
Wegovy's active ingredient, semaglutide, is a GLP-1 receptor agonist. GLP-1 is a gut hormone released naturally after eating; it signals fullness to the brain and slows the passage of food through the stomach. The medicine mimics this effect at a sustained level, which means appetite falls significantly and most people eat considerably less without feeling deprived. If you're wondering whether Wegovy actually helps your metabolism or simply reduces how much you eat, the answer is that less energy in over weeks and months is the engine of the weight loss, not a faster idle speed in your cells.
For a fuller look at semaglutide's pharmacology, our semaglutide overview covers the mechanism in detail. The NHS medicines page for semaglutide also explains how the medicine works in plain language, and is updated in line with current clinical guidance.
There's a complication worth being honest about. When the body loses weight (through any method) resting energy expenditure tends to fall. This is partly mechanical (a smaller body requires fewer calories to maintain) and partly adaptive: the body responds to a sustained calorie deficit by becoming more efficient. Some research suggests this adaptive component can persist beyond the weight-loss phase.
There is also the question of lean mass. Significant weight loss can include muscle alongside fat, and muscle tissue burns more calories at rest than fat tissue does. This is one reason prescribers and dietitians consistently recommend adequate protein at every meal and some form of resistance or strength activity during treatment, protecting lean mass helps protect your resting calorie burn. If you want to understand more specifically how Wegovy affects your metabolism across these broader changes, that page goes into more depth alongside our guidance on semaglutide and metabolism.
None of this is unique to Wegovy; it applies to weight loss generally. The relevant question is whether the treatment's benefits (reduced hunger, documented clinical-trial weight loss, and for some patients a reduced risk of cardiovascular events) outweigh these considerations given your individual circumstances. That is exactly what a prescriber's assessment is designed to work through.
The STEP 1 trial, published in the New England Journal of Medicine in 2021, followed 1,961 adults with obesity or overweight and at least one weight-related condition over 68 weeks. Participants using semaglutide 2.4mg lost an average of around 15% of body weight compared with roughly 2.4% on placebo, alongside lifestyle support. That is a substantial difference, and it reflects a sustained reduction in energy intake rather than an elevated rate of calorie burning.
A newer higher dose, 7.2mg, was approved by the MHRA in early 2026 and has reported approximately 20.7% average weight loss over 72 weeks in trials, approaching the figures seen with tirzepatide. If you're comparing the two treatments, a closer look at Wegovy's clinical impact sets out what that evidence means practically.
One practical note: your Wegovy pen lives in the fridge door between doses, which makes it easy to build the weekly injection into a fixed routine, the same evening, same spot, same habit. That kind of consistency matters more than most people expect in treatment adherence.
Wegovy is a prescription-only medicine. Questions about your specific metabolic health, any existing conditions, or how to get started belong with a clinician. If you'd like to understand the full picture of what private treatment involves, our Wegovy treatment page is a good starting point, and you can read about the people overseeing care at our clinical team page.
If you'd like to discuss whether Wegovy is clinically suitable for you, start your free consultation with our GPhC-registered prescribers, reviewed the same day, no waiting list.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.